Microsatellite instability-high status may make patients suitable candidates to receive agents like pembrolizumab, according to Steven Bialick, DO.
Steven Bialick, DO
Advertisement
Articles by Steven Bialick, DO
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Grants Orphan Drug Designation to Tovecimig for Biliary Tract Cancer
2
FDA Issues Second CRL for RP1/Nivolumab in Advanced Melanoma
3
Targeting the Tumor Ecosystem to Create Pan–Solid Tumor Vulnerability
4
Highlighting Impactful ASCO GU Research Across Disease States
5